Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION			
LAST NAME:	FIRST NAME:		
PHONE NUMBER:	DATE OF BIRTH:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
PATIENT INSURANCE ID NUMBER:			

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): ____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:

PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
REQUESTER (if different than prescriber):	OFFICE CONTACT PERSON:		

ΜΕΠΙΟΛΤΙΟΝ	DISPENSING INFORMATION	
WEDICATION		

MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF	QUANTITY:	
		THERAPY/REFILLS:		
NEW THERAPY RENEWAL IF RENEWAL : DATE THERAPY INITIATED:				
DURATION OF THERAPY (SPECIFIC DATES):				
Continued on next page				

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 5.15.2025 CAT009



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:				
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? VES (if yes, complete below) NO					
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
 Type II diabetes for blood glucose control Heart Failure with diabetes Type II diabetes with established cardiovascular disease and/or with additional cardiovascular risk Chronic kidney disease with Type II diabetes 					
Other diagnosis:	ICD-10 Code(s):				
3. REQUIRED CLINICAL INFORMATO SUPPORT A PRIOR AUTHORIZ	ATION: PLEASE PROVIDE ALL REL ZATION.	EVANT CLINICAL INFORMATION			
Is patient going to be using drug	in combination with a clinical trial?	P 🗌 Yes 🗌 No			
For patient with Type II Diabetes of	only, answer the following:				
Is the patient's estimated glomerular filtration rate (GFR) below 60 mL/min/1.73 m2?* □ Yes □ No *Please provide documentation.					
Is the patient on dialysis? <pre>□ Yes</pre>	□ No				
Was the patient's hemoglobin A1C (HbA1c) 7.0% or greater prior to therapy (HbA1c must be taken within the past 6 months if the patient has not been on this treatment previously)?* u Yes u No *Copy of HbA1c level required.					
Is the patient currently on metformin?* u Yes u No					
Does the patient had an inadequate response or intolerance to metform?					
Does the patient have at least one of the following contraindication to metformin? □ Yes □ No (Please Check one) □ Estimated glomerular filtration rate (GFR) less than or equal to 30 mL/min/1.73 m2					
 Advanced liver disease with cirrhosis, portal hypertension, ascites, and/or hepatic encephalopathy 					

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 5.15.2025 CAT009



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: ______ MEMBER'S FIRST NAME: ____

For patient with Type II diabetes with established cardiovascular disease and/or risks, answer the following:

Is the patient 40 years of age or older?

Yes
No Does patient have Type II diabetes?
Que Yes
Que No

Does the patient have established cardiovascular disease as described as ischemic heart disease and/or cerebrovascular disease and/or peripheral arterial disease?

Yes
No
*Please provide documentation.

Is the patient a 55 year old(or older) male with dyslipidemia, hypertension and/or who smokes 5 or more cigarettes/day?

Yes
No

Is the patient a 60 year old(or older) female with dyslipidemia, hypertension and/or who smokes 5 or more cigarettes/day?
Que Yes
Que No

For patient with heart failure with diabetes, answer the following:

Has patient ever had NYHA class II, III, or IV symptoms of heart failure?
Second Yes ON * Please provide documentation

Does patient have ejection fraction of 49% or less?
□ Yes □ No *Please provide documentation Does patient have Type II diabetes?
Ves
No

Does patient have ejection fraction of greater than 49% \square Yes \square No **Please provide documentation.*

Does patient have a NT-proBNP greater than 300pg/ml?
Ves
No Please provide documentation.

For patients with A-fib, is the NT-proBNP greater than 600pg/ml?
Yes Destrict Yes Provide documentation.

IF NT-proBNP not available, does patient have a BNP >100pg/ml?
• Yes
• No Please submit chart documentation.

If NT-proBNP not available and patient has Atrial fibrillation (AF), does patient have a BNP >100pg/ml?
• Yes
• No Please submit chart documentation

Does the patient have structural heart disease such as one or more of the following:?
• Yes • No Please provide documentation from echocardiogram.

- □ LA width >3.8cm
- \Box LA length >5.0 cm
- □ LA area >20cm2
- □ LA volume >55ml
- □ LA volume index >29ml/m2

Does patient have and eGFR less than 25ml/min/1.73m²?
Ves
No

Has patient had a heart translplant or complex congenital heart disease?
Yes
No

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 5.15.2025 CAT009



XigduoXR (dapagliflozin/metformin) **Prior Authorization Request Form** Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME:

Does patient have severe pulmonary disease including severe COPD, requiring home oxygen therapy for their COPD, chronic nebulizer therapy or chronic oral steroid therapy for treatment of their severe COPD?
_ Yes
_ No Please submit chart documentation.

Does patient have severe pulmonary disease including WHO group 1 primary pulmonary hypertension?
Que Yes
No Please submit chart documentation.

Does patient have any other condition or diagnosis causing patient's heart failure symptoms such as?
Yes
No Please submit chart documentation.

□ Anemia

hypothyroidism

- Known infiltrative cardiomyopathy(e.g. amyloid sarcoid, lymphoma, endomyocardial fibrosis)
- □ Active mvocarditis
- □ Constrictive pericarditis
- □ Cardiac tamponade
- Known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy
- Arrhythmogenic right ventricular cardiomyopathy/dysplasia
- Uncorrected primary valvular disease

For patients with chronic kidney disease with Typell diabetes, answer the following:

Has patient had chronic kidney disease for 3 or more months?
Yes
No *Please provide documentation.

Does patient have Type II diabetes?
Ves
No

Does patient have and estimated GFR(eGFR) that equals between 20 - 45ml/min/1.73m² (inclusive)? Yes D No *Please provide documentation.

Does patient have and estimated GFR(eGFR) greater than or equal to 45 to less than or equal to 9045ml/min/1.73m² with urinary albumin:creatinine ratio greater than or equal to 200mg/G or protein:creatinine ratio greater than or equal to 300mg/G?
Set No *Please provide documentation.

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ Date: ____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

> FAX THIS FORM TO: 800-424-7640 MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

